DoW Toxic Exposures Clinical Trial Award
About the Opportunity
The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) supports the advancement, execution, and analysis of clinical trials with the potential to significantly impact the prevention, treatment, or management of symptoms, diseases, or conditions associated with or resulting from military-related toxic exposures.
Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) to large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.
Distinctive Features
The FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO) to encourage meaningful and productive collaborations. One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. This option supports interdisciplinary partnerships, such as those between clinicians and research scientists, to accelerate the movement of promising interventions or knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts.
Eligibility
- Unrestricted (open to any type of entity, subject to additional clarification in the "Additional Information on Eligibility" section).
Funding Details
- Estimated Total Program Funding: $4,500,000
- Expected Number of Awards: 1
- Assistance Listing: 12.420 -- Military Medical Research and Development
- Cost Sharing or Matching Requirement: No
Key Dates:
- Posted Date: May 21, 2026
- Last Updated Date: May 21, 2026
- Current Closing Date for Applications: November 19, 2026
- Archive Date: December 19, 2026
Additional Information
For more details, visit the TERP pre-announcement page.
If you have difficulty accessing the full announcement electronically, contact the eBRAP Help Desk at 301-682-5507 or help@eBRAP.org.